OriCAR-633

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameOriCAR-633

Drug Alias NameOriCAR633OriCAR-633OriC633OriC-633

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > T cell engagers

Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacementsAlpha-fetoprotein inhibitors +[4]

TargetsGlypican-3Alpha-fetoproteinT cell surface glycoprotein CD3

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesOriCell Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A